Baring Private Equity Asia said it has agreed to acquire Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise value of Y77.3 billion $670 million.
Saitama-headquartered Bushu, which makes drugs for third parties on a contract basis, expanded its capacity to 10 billion tablet dosages per year by buying a plant in Misato in March from Japanese drug company Eisai, which was cutting costs.
Japan’s Pharmaceutical Affairs Law changed in...